Clinical Trial Update: FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A terminated Phase 2 trial evaluated FR901228 alone or with Rituximab and Fludarabine in relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• FR901228 (romidepsin)
• Fludarabine (Fludarabine)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Status: TERMINATED